Journal article
Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens
European journal of clinical microbiology & infectious diseases, Vol.23(10), pp.772-775
10/2004
DOI: 10.1007/s10096-004-1214-5
PMID: 15605184
Abstract
In two prospective, randomized studies intravenous (IV)/oral (PO) moxifloxacin (400 mg q.i.d.) was compared to IV/PO antimicrobial comparator agents for the treatment of hospitalized patients with community-acquired pneumonia. Reported here are the pooled data for the sub-population with atypical pathogens. Of 101 intent-to-treat patients with atypical pathogens, a total of 39 moxifloxacin-treated and 47 comparator-treated subjects were microbiologically valid and included in the analysis. Clinical and bacteriological success rates were 95% for the moxifloxacin-treated and 94% for the comparator-treated subjects at the test-of-cure visit. The results indicate IV/PO moxifloxacin (400 mg q.i.d.) is an effective monotherapy for patients with CAP due to atypical pathogens.
Details
- Title: Subtitle
- Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens
- Creators
- G Hoeffken - University Hospital Carl Gustav CarusD Talan - Ronald Reagan UCLA Medical CenterL S Larsen - Fusion Clinical TrialsS Peloquin - Hospital FleuryS H Choudhri - BayerD Haverstock - BayerP Jackson - BayerD Church - Bayer
- Resource Type
- Journal article
- Publication Details
- European journal of clinical microbiology & infectious diseases, Vol.23(10), pp.772-775
- DOI
- 10.1007/s10096-004-1214-5
- PMID
- 15605184
- ISSN
- 0934-9723
- eISSN
- 1435-4373
- Language
- English
- Date published
- 10/2004
- Academic Unit
- Emergency Medicine; Internal Medicine
- Record Identifier
- 9984296977102771
Metrics
10 Record Views